...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone


BREAKING: Empower Clinics Announces Joint Venture with Heritage Cannabis for the Production of Hemp Derived CBD Oils and Formulated Products in Oregon USA

  • Heritage, via its wholly owned subsidiary Purefarma Solutions Inc., will install extraction units and related downstream extraction equipment inside Empower’s existing 5,000 sq. ft. licenced hemp processing facility in Sandy, OR.
  • JV will be equally funded by both companies with Heritage investing an initial $500,000 for start-up funds, as the build out completes and the JV secures high quality hemp supply from local growers
  • Once operational, the JV will begin producing proprietary branded products for Empower’s corporately owned physician staffed health clinics in Washington State, Oregon, Nevada and Arizona

Epw logo1

Hub On AGORACOM / Read Release

Message: Article on NASH Liver Disease

That's a great article Iconoclast. Thanks for sharing. NASH is a complex disease. I have no opinion right now on apabetalone's promise for NASH. 

One piece of data that Resverlogix previously presented that caught my eye was a study with primary human hepatocytes in which apabetalone robustly suppressed the expression of FXR. FXR is the same target that is activated by Intercept's obeticholic acid (OCA). We all know that apabetalone does a lot more than just suppress FXR and that NASH is much more than just FXR, but one could argue that suppression of FXR by apabetalone goes in the wrong direction for a NASH therapy. Also, the apabetalone/FXR observations were just in primary cells and not in a whole animal or human. In vitro doesn't always translate to in vivo.


New Message
Please login to post a reply